% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • maxcoatinc maxcoatinc Oct 14, 2013 2:58 PM Flag

    Will JNJ earnings and management statements about Ibrutinib have a greater influence on PCYC

    price direction than GILD news had on PCYC, which in the end was very little. It is still all about what the large mutual funds holding such as Fidelity BIOTECH and others do with PCYC.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • YES.On Friday, Goldman Sachs analyst Jami Rubin upgraded the stock to neutral from sell, noting that the success of several recent drug launches bodes well for simeprevir and ibrutinib, two products currently awaiting FDA approval. Simeprevir is a hepatitis C drug that J&J eventually hopes to combine with a drug it just acquired from GlaxoSmithKline (GSK) to form an all-oral therapy for hepatitis C. Ibrutinib is a treatment for blood cancer developed by Pharmacyclics (PCYC), which won a "breakthrough therapy" designation from the FDA to speed up its review process.

      Despite some good news about Gilead Sciences ' (GILD) rival idelalisib drug last week, Goldman Sachs analyst Navdeep Singh set his peak annual sales estimate for ibrutinib at $7.5 billion.

      Sentiment: Strong Buy

      • 1 Reply to jgmtruth
      • GILD's HepC is predicted avg. "PEAK SALES" of $7.4B :) The big buzz now surrounds Gilead's hepatitis C drug Sofosbuvir. Already touted as a megablockbuster, an FDA decision on sofosbuvir is expected in December, around the time competitor Johnson & Johnson hears about its simeprevir. The average analyst estimate for peak sales of sofosbuvir is $7.4 billion.

        And just icing on the cake..:)))) GLTA big market for both!! :))

257.100.00(0.00%)Apr 23 3:59 PMEDT